AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
AstraZeneca's triplet combo succeeds in some liver cancer patients
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA approval…
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new phase 3…
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The…
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
AstraZeneca seeks a narrower path for failed antibody; Imfinzi and Tremfya label expansions
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
